查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018619

次世代定序(NGS) 樣品製備市場：2026 年至 2032 年全球市場預測，按產品、工作流程、NGS 技術、樣品類型、應用和最終用戶分類

Next-Generation Sequencing Sample Preparation Market by Product, Workflow, NGS Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計次世代定序樣品製備市場在 2025 年的價值為 63.4 億美元，在 2026 年成長至 71 億美元，到 2032 年達到 145.2 億美元，年複合成長率為 12.55%。

主要市場統計數據
基準年 2025 63.4億美元
預計年份：2026年 71億美元
預測年份 2032 145.2億美元
複合年成長率 (%) 12.55%

本次演講將探討最佳化樣本製備工作流程的策略挑戰，以確保資料完整性、加速研究並改善臨床定序結果。

次世代定序(NGS) 已從一項創新的實驗室技術發展成為現代生物學、診斷學和應用研究的基石。隨著定序處理能力和分析複雜性的不斷提升，定序領先的各項流程——包括檢體採集、核酸提取、文庫建構、標靶富集和品管——已成為決定數據準確性和可解釋性的關鍵因素。穩健的樣本製備能夠確保目標生物訊號可靠地保存並穩定地傳遞至下游儀器，從而降低分析變異性，並加速將原始序列讀段轉化為可操作見解的過程。

本研究評估了技術創新、自動化和標準化如何重塑樣品製備實踐並影響實驗室運作模式。

在技​​術創新、監管環境不斷演變以及終端用戶對可重複、高品質數據的日益成長的需求的推動下，次世代定序測序的樣本製備領域正經歷著快速而多方面的變革。試劑化學和酶學的進步使得以更少的投入高效樣品製備成為可能，並拓展了可分析的樣本類型。同時，自動化和微流體技術的改進降低了人為操作的誤差，提高了定序通量。隨著定序擴展到群體層級研究和常規臨床診斷領域，這一點尤其重要。

本研究檢視了關稅變化和貿易政策轉變對試劑採購、籌資策略和生產連續性的營運和供應鏈影響。

關稅調整和貿易政策變化會立即對次世代定序樣本製備所需的試劑、儀器和耗材的供應鏈造成壓力。在美國，2025年宣布或實施的關稅措施，為從國際供應商採購專用酵素、塑膠和儀器組件的機構帶來了新的成本考量和物流複雜性。為了應對這些變化，採購團隊正在審查供應商合約、前置作業時間緩衝和緊急儲備，以降低中斷風險並維持服務連續性。

它提供細粒度的細分訊息，將產品類型、工作流程、技術、樣品分類、應用和最終用戶優先級聯繫起來，以指導採購和開發。

要整體情況了解樣品製備，需要從多個細分維度進行深入觀點，這些維度會影響採購行為、工作流程設計和技術相容性。基於產品考量，實驗室會將儀器、試劑和耗材以及服務作為既獨立又相互依存的類別進行評估。這些因素共同決定了整體工作流程的績效和供應商的價值提案。儀器決定了處理能力和自動化所需的技術基礎；試劑和耗材影響化學性能和批間一致性；而包括安裝和方法驗證在內的服務則有助於加快部署速度並提高運行可靠性。

本文說明了區域法規結構、基礎設施投資和在地採購趨勢如何影響世界各地的採購重點和工作流程實施。

區域趨勢在塑造籌資策略、監管合規性和樣本製備實踐的演變方面發揮著至關重要的作用。在美洲，對臨床定序基礎設施和轉化研究中心的投資正在推動對自動化工作流程和經驗證試劑盒的需求，這些工具能夠支援高通量、臨床層級的操作。該地區的檢查室通常優先考慮與現有設備的快速整合以及全面的售後服務支持，這體現了他們對臨床應用和大規模研究舉措的高度重視。

本分析探討了整合解決方案、夥伴關係策略和檢驗的績效數據如何在樣品製備生態系統中創造供應商之間的競爭差異化。

樣本製備領域的競爭格局呈現出多元化的特點，既有成熟的儀器製造商，也有專業的試劑供應商，還有提供端到端工作流程解決方案和技術支援的服務供應商。許多主要企業專注於整合解決方案，將儀器、檢驗的試劑組和基於軟體的品管捆綁在一起，從而降低終端用戶整合風險，並加速在臨床和高通量研究環境中的部署。此外，一些公司還專注於特定的化學方法或新型萃取技術，以應對諸如低起始量樣本或高度分解的核酸等特定挑戰。

本文檔為供應商和實驗室提供了概念驗證、可操作的方法，以增強整個樣品製備工作流程中的檢驗、韌性和以客戶為中心的服務交付。

產業領導企業可以採取一系列切實可行的措施，在技術、商業性和營運方面鞏固自身地位。首先，投資於工作流程檢驗和互通性測試，以確保儀器、試劑盒和耗材在各種檢查室環境中都能如預期運作。這可以降低客戶部署風險並縮短合格週期。其次，透過發布獨立的檢驗研究和提供清晰的品管指標，優先考慮性能數據的透明度。這使採購團隊能夠進行基於數據的比較，並增強對新解決方案的信心。

概述了嚴謹透明的研究途徑，該方法整合了初步訪談、技術文獻和供應商文檔，以確保獲得可操作和可重複的見解。

本研究整合了來自一手訪談、技術文獻和產品文件的定性和定量信息，旨在全面了解樣品製備流程和供應商策略。研究的關鍵要素包括與來自學術界、臨床界和商業領域的實驗室負責人、採購經理、試劑和儀器製造商的研發經理以及技術服務經理進行結構化討論。這些對話探討了工作流程挑戰、驗證流程、供應商選擇標準和供應鏈考量，從而提供了對產業趨勢的第一手見解。

為了維持定序的可靠性和轉換影響，我們總結了優先採用檢驗、互通性且穩健的樣本製備技術的策略需求。

總之，對於任何尋求可靠、高品質定序數據的機構而言，最佳化樣品製備都是至關重要的策略重點。試劑、自動化和品管（QC）方面的技術改進直接影響下游分析的可重複性和靈敏度，而供應鍊和監管趨勢則影響採購政策和營運韌性。因此，相關人員必須將樣品製備視為策略性投資，因為它會影響實驗成功率、檢查室能力和科學發現的可靠性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章次世代定序(NGS) 樣品製備市場：依產品分類

  • 裝置
  • 試劑和耗材
  • 服務

第9章次世代定序(NGS) 樣品製備市場：依工作流程分類

  • 樣品製備與擴增
  • 圖書館定量分析和品管
  • 核酸萃取
  • 目標濃度

第10章次世代定序(NGS) 樣品製備市場（依 NGS 技術分類）

  • ChIP定序（染色質免疫沉澱分析法）
  • EXOME定序
  • 甲基化序列
  • RNA定序（RNA-Seq）
  • 目標序列
  • 全基因組定序（WGS）

第11章 依樣本類型次世代定序(NGS) 樣本製備市場

  • DNA
  • RNA

第12章次世代定序(NGS) 樣品製備市場：依應用領域分類

  • 農業基因組學
  • 動物科學與獸醫學概覽
  • 臨床診斷
  • 臨床研究和藥物開發
  • 消費者基因體學
  • 法醫學

第13章次世代定序(NGS) 樣品製備市場：依最終使用者分類

  • 學術和研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第14章次世代定序(NGS) 樣品製備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章次世代定序(NGS) 樣品製備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章次世代定序(NGS) 樣品製備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國次世代定序（NGS）樣品製備市場

第18章：中國次世代定序（NGS）樣品製備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Azenta Life Sciences
  • BGI Genomics Co., Ltd.
  • Biodiscovery, LLC
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GenScript Biotech Corporation
  • Hamilton Bonaduz AG
  • Illumina, Inc.
  • LGC Biosearch Technologies
  • Merck KGaA
  • Meridian Bioscience, Inc
  • New England Biolabs, Inc
  • NimaGen BV
  • Omega Bio-tek, Inc.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • Parse Biosciences
  • PerkinElmer, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Standard BioTools Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
  • Zymo Research Corporation
Product Code: MRR-2214614769A0

The Next-Generation Sequencing Sample Preparation Market was valued at USD 6.34 billion in 2025 and is projected to grow to USD 7.10 billion in 2026, with a CAGR of 12.55%, reaching USD 14.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.34 billion
Estimated Year [2026] USD 7.10 billion
Forecast Year [2032] USD 14.52 billion
CAGR (%) 12.55%

Introducing the strategic imperative for optimizing sample preparation workflows to safeguard data integrity, accelerate research, and enhance clinical sequencing outcomes

Next-generation sequencing (NGS) has evolved from a transformative laboratory technique into a foundational pillar for modern biology, diagnostics, and applied research. As sequencing throughput and analytical complexity have increased, the processes that precede sequencing-sample collection, nucleic acid extraction, library construction, target enrichment, and quality control-have emerged as critical determinants of data fidelity and interpretability. Robust sample preparation ensures that the biological signal of interest is preserved and presented consistently to downstream instruments, thereby reducing analytical variability and accelerating the translation of raw sequence reads into actionable insights.

This report introduces the strategic importance of sample preparation by examining the confluence of technological advancement, regulatory scrutiny, and operational demands that now shape practice in academic, clinical, and commercial laboratories. It emphasizes that improvements in reagents, automation, and protocol standardization have immediate impacts on turnaround time, reproducibility, and cost-per-result. Consequently, laboratory leaders and procurement teams must evaluate sample preparation not as a peripheral supply cost but as an integral component of the sequencing value chain.

Finally, the introduction sets the stage for deeper analysis by framing key questions for stakeholders: how do different workflows and consumables influence analytical outcomes; which innovations meaningfully reduce pre-analytical errors; and how should organizations prioritize investments to align with scientific objectives and regulatory expectations. With that framing in place, subsequent sections explore the landscape shifts, regulatory headwinds, segmentation intelligence, regional dynamics, competitive positioning, and practical recommendations that collectively inform strategic decisions.

Assessing how technological innovation, automation, and standardization are reshaping sample preparation practices and influencing laboratory operational models

The landscape of sample preparation for next-generation sequencing is undergoing rapid, multidimensional change driven by technological innovation, evolving regulatory environments, and the increasing expectations of end users for reproducible, high-quality data. Advances in reagent chemistry and enzymology are enabling more efficient library preparation with lower input requirements, thereby expanding the range of sample types that can be interrogated. Concurrently, improvements in automation and microfluidic handling are reducing manual variability and increasing throughput, which is particularly consequential as sequencing scales to population-level studies and routine clinical diagnostics.

These technological shifts are accompanied by a growing emphasis on standardization and interoperability. Inter-laboratory reproducibility is now a central metric for both clinical validation and collaborative research, prompting suppliers and laboratories to invest in validated kits, closed workflows, and integrated QC solutions. The convergence of wet-lab improvements and informatics-enabled QC checkpoints strengthens the traceability of samples from collection to data deliverables. Moreover, emerging approaches such as targeted enrichment refinement and low-input library methods are enabling new applications, including circulating tumor DNA profiling and single-cell analyses, which demand specialized sample preparation strategies.

As a result, organizations are rethinking procurement and operational models. There is a clear shift toward bundled solutions that integrate instruments, reagents, and services in order to minimize compatibility issues and accelerate time-to-result. This shift has strategic implications for suppliers and end users alike: suppliers must demonstrate workflow compatibility and regulatory readiness, while laboratories must balance flexibility for bespoke protocols against the efficiencies of standardized, validated kits and platforms. Ultimately, these transformative shifts are redefining expectations for performance, reliability, and lifecycle support across the sample preparation ecosystem.

Examining the operational and supply chain consequences of tariff changes and trade policy shifts on reagent sourcing, procurement strategies, and production continuity

Tariff changes and trade policy adjustments can exert immediate pressure on the supply chains that underpin reagents, instruments, and consumables necessary for next-generation sequencing sample preparation. In the United States, tariff measures announced or implemented in 2025 have introduced new cost considerations and logistical complexity for organizations that source specialized enzymes, plastics, and instrumentation components from international suppliers. These developments have prompted procurement teams to reassess vendor contracts, lead time buffers, and contingency inventories to mitigate disruption risk and maintain continuity of service.

In response to tariff-driven uncertainty, many stakeholders are diversifying supplier networks and exploring regional sourcing arrangements to reduce exposure to cross-border duties. Some laboratories have accelerated qualification of alternative reagent formats and vendor-agnostic consumables to preserve operational agility. At the same time, manufacturers are responding by adapting pricing strategies, localizing certain aspects of production, and expanding distributor partnerships to offset the immediate impacts of trade-related costs. These adjustments often come with transitional friction, including qualification cycles and potential variances in lot-to-lot performance that must be managed through rigorous QC protocols.

From an operational perspective, institutions are prioritizing supply chain resilience alongside scientific performance. This entails developing risk assessments that account for tariff volatility, lead time variability, and single-source dependencies. Simultaneously, procurement and laboratory leadership are increasingly collaborating to balance short-term continuity measures with long-term strategic sourcing, ensuring that sample preparation workflows remain robust in the face of ongoing policy and trade fluctuations. These collective responses underscore the importance of flexible procurement strategies and vendor engagement practices to preserve experimental integrity and service delivery.

Delivering nuanced segmentation intelligence that links product types, workflows, technologies, sample classes, applications, and end user priorities to guide procurement and development

Understanding the sample preparation landscape requires a granular view across multiple segmentation axes that influence purchasing behavior, workflow design, and technical compatibility. Based on product considerations, laboratories evaluate instruments, reagents and consumables, and services as distinct yet interdependent categories that together determine total workflow performance and vendor value propositions. Instruments set the technical baseline for throughput and automation; reagents and consumables govern chemistry performance and lot consistency; and services, including installation and method validation, enable accelerated adoption and operational reliability.

When viewed through the workflow lens, stakeholders place emphasis on library preparation and amplification, library quantification and quality control, nucleic acid extraction, and target enrichment as sequential phases where optimization can yield disproportionate benefits in data quality. Library preparation and amplification techniques are central to preserving representation and reducing bias, whereas robust quantification and QC prevent costly sequencing failures. Nucleic acid extraction remains the foundational step, with extraction efficiency and inhibitor removal critically shaping downstream success. Target enrichment approaches, meanwhile, dictate the specificity and sensitivity of downstream analyses for targeted panels and variant detection.

NGS technology segmentation further refines decision criteria; approaches such as ChIP sequencing, exome sequencing, methylation sequencing, RNA sequencing, targeted sequencing, and whole genome sequencing each impose different requirements for input quality, fragment size, and enrichment strategies. Sample type segmentation between DNA and RNA highlights divergent handling needs and stabilization protocols, with RNA workflows typically demanding more stringent preservation and QC. Application-driven priorities-ranging from agricultural genomics and animal science to clinical diagnostics, clinical research and drug development, consumer genomics, and forensics-shape validation requirements, throughput tolerances, and regulatory scrutiny. Finally, end users including academic and research institutions, hospitals and clinics, and pharmaceutical and biotechnology companies demonstrate unique purchasing rationales and service expectations, driving suppliers to offer differentiated commercial models and technical support to meet these varied needs.

Explaining how regional regulatory frameworks, infrastructure investments, and local sourcing trends shape procurement priorities and workflow adoption across global territories

Regional dynamics play a pivotal role in shaping procurement strategies, regulatory alignment, and the evolution of sample preparation practices. In the Americas, investment in clinical sequencing infrastructures and translational research hubs is fostering demand for automated workflows and validated kits that support high-throughput and clinical-grade operations. Laboratories in this region often emphasize rapid integration with existing instrumentation and robust after-sales support, reflecting the heavy focus on clinical adoption and large-scale research initiatives.

Across Europe, the Middle East & Africa, regulatory heterogeneity and varied healthcare infrastructures create a landscape where compliance pathways and localized validation are critical. Laboratories in this combined region increasingly seek solutions that facilitate cross-border collaboration while meeting stringent regional compliance frameworks. There is a pronounced interest in flexible workflows that can be adapted to both resource-rich urban centers and decentralized facilities that require reliable, low-complexity protocols.

In the Asia-Pacific region, rapid expansion of sequencing capacity and investments in genomics-driven healthcare and agriculture are driving demand for cost-effective, high-throughput sample preparation solutions. Local manufacturing and supply chain initiatives in several countries are beginning to influence procurement choices, encouraging suppliers to consider regional production and distribution strategies. Across all regions, however, the interplay between regulatory expectations, reimbursement environments, and research priorities shapes how organizations prioritize investments in instrumentation, reagents, and services for sample preparation.

Profiling how integrated solutions, partnership strategies, and validated performance data create competitive differentiation among suppliers in the sample preparation ecosystem

Competitive dynamics in the sample preparation space are characterized by a mix of established instrument manufacturers, specialized reagent suppliers, and service providers that deliver end-to-end workflow solutions and technical support. Many leading players focus on integrated offerings that bundle instruments with validated reagent kits and software-enabled quality control, thus reducing integration risk for end users and accelerating adoption in clinical and high-throughput research settings. Others specialize in niche chemistries or novel extraction technologies that address specific pain points, such as low-input samples or highly degraded nucleic acids.

Partnerships and channel strategies are becoming central to company differentiation. Suppliers that cultivate strong distributor networks, localized technical support, and co-development relationships with end users can more rapidly respond to demand variability and regulatory needs. Additionally, investments in method validation and published performance data increasingly serve as decision-making criteria for laboratory directors and procurement teams. Companies that demonstrate reproducible results across multiple independent studies enhance confidence among potential buyers and reduce the perceived risk associated with switching reagents or platforms.

Innovation pipelines are also influenced by cross-sector collaboration. Collaborations between reagent companies, instrument OEMs, and contract research organizations are enabling modular solutions that combine best-in-class components with managed services. This collaborative approach often yields accelerated product refinement and a broader evidence base for clinical and research applications. Consequently, competitive advantage accrues to organizations that can deliver demonstrable improvements in workflow efficiency, reproducibility, and lifecycle support, while maintaining flexibility for customization where necessary.

Presenting evidence-based, practical initiatives for vendors and laboratories to enhance validation, resilience, and customer-centric service delivery across sample preparation workflows

Industry leaders can adopt a set of pragmatic, actionable measures to strengthen their position across technical, commercial, and operational dimensions. First, invest in workflow validation and interoperability testing to ensure that instruments, kits, and consumables function predictably across diverse laboratory environments. This reduces implementation risk for customers and shortens qualification cycles. Second, prioritize transparency in performance data by publishing independent validation studies and providing clear QC metrics, enabling procurement teams to make evidence-based comparisons and accelerating trust in new solutions.

Third, enhance supply chain resilience by diversifying supplier bases, qualifying alternative reagent formats, and developing regional distribution capabilities to mitigate exposure to trade disruptions. Fourth, expand service offerings that combine technical training, method transfer, and post-sale support to maximize uptime and reduce user error. Fifth, engage proactively with regulatory stakeholders and clinical partners to anticipate compliance requirements and align product development with clinical evidence needs. By doing so, organizations can position themselves as trusted collaborators for translational research and diagnostic adoption.

Finally, adopt a customer-centric commercial model that balances standardized, validated kits for rapid deployment with configurable solutions for specialized applications. This hybrid approach supports scalability while preserving the flexibility required by advanced research programs. Implementing these recommendations enhances operational robustness, strengthens customer relationships, and accelerates the translation of technical innovations into reliable laboratory practice.

Outlining the rigorous, transparent research approach that integrates primary interviews, technical literature, and supplier documentation to ensure actionable and reproducible findings

This research synthesizes qualitative and quantitative inputs from primary interviews, technical literature, and product documentation to develop a comprehensive understanding of sample preparation practices and supplier strategies. Primary engagement included structured discussions with laboratory directors, procurement leads, R&D heads at reagent and instrument manufacturers, and technical service managers across academic, clinical, and commercial settings. These conversations explored workflow pain points, validation practices, vendor selection criteria, and supply chain considerations, providing first-hand context for observed industry dynamics.

Secondary sources comprised peer-reviewed publications, regulatory guidance documents, and manufacturer technical notes that describe methods, performance characteristics, and validation approaches. Analytical emphasis was placed on method comparability, reproducibility metrics, and the operational implications of reagent and instrument choices. Additionally, the research team evaluated product integration and support offerings through supplier documentation and publicly available technical information to triangulate claims with laboratory experiences.

The analytical framework combined thematic synthesis with comparative evaluation across segmentation axes to identify common drivers of adoption, technical trade-offs, and supplier differentiation. Throughout the process, attention was paid to ensuring methodological transparency and reproducibility of findings, with a focus on delivering insights that inform strategic decisions without relying on proprietary commercial estimations.

Summarizing the strategic imperative to prioritize validated, interoperable, and resilient sample preparation practices to sustain sequencing reliability and translational impact

In conclusion, optimizing sample preparation is an indispensable strategic priority for any organization seeking reliable, high-quality sequencing data. Technical refinements in reagents, automation, and QC have a direct bearing on the reproducibility and sensitivity of downstream analyses, while supply chain and regulatory dynamics shape procurement choices and operational resilience. Stakeholders must therefore evaluate sample preparation as a strategic investment that influences experiment success rates, laboratory throughput, and the credibility of scientific findings.

The converging trends toward integrated solutions, regional sourcing adjustments, and evidence-based validation signal a maturing ecosystem that rewards transparency, interoperability, and service excellence. Organizations that proactively address compatibility, validation, and supply continuity will be better positioned to capitalize on scientific opportunities and to mitigate operational disruptions. Ultimately, judicious investments in sample preparation practices and supplier partnerships translate into more reliable sequencing outputs, accelerated translational impact, and enhanced confidence among clinical and research users.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Sequencing Sample Preparation Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
  • 8.3. Services

9. Next-Generation Sequencing Sample Preparation Market, by Workflow

  • 9.1. Library Preparation & Amplification
  • 9.2. Library Quantification/QC
  • 9.3. Nucleic Acid Extraction
  • 9.4. Target Enrichment

10. Next-Generation Sequencing Sample Preparation Market, by NGS Technology

  • 10.1. ChIP Sequencing (Chromatin Immunoprecipitation)
  • 10.2. Exome Sequencing
  • 10.3. Methylation Sequencing
  • 10.4. RNA Sequencing (RNA-Seq)
  • 10.5. Targeted Sequencing
  • 10.6. Whole Genome Sequencing (WGS)

11. Next-Generation Sequencing Sample Preparation Market, by Sample Type

  • 11.1. DNA
  • 11.2. RNA

12. Next-Generation Sequencing Sample Preparation Market, by Application

  • 12.1. Agricultural Genomics
  • 12.2. Animal Science & Veterinary Research
  • 12.3. Clinical Diagnostics
  • 12.4. Clinical Research & Drug Development
  • 12.5. Consumer Genomics
  • 12.6. Forensics

13. Next-Generation Sequencing Sample Preparation Market, by End User

  • 13.1. Academic & Research Institutions
  • 13.2. Hospitals & Clinics
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Next-Generation Sequencing Sample Preparation Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Next-Generation Sequencing Sample Preparation Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Next-Generation Sequencing Sample Preparation Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Next-Generation Sequencing Sample Preparation Market

18. China Next-Generation Sequencing Sample Preparation Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies, Inc.
  • 19.6. Azenta Life Sciences
  • 19.7. BGI Genomics Co., Ltd.
  • 19.8. Biodiscovery, LLC
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Charles River Laboratories International, Inc
  • 19.11. Danaher Corporation
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. GenScript Biotech Corporation
  • 19.14. Hamilton Bonaduz AG
  • 19.15. Illumina, Inc.
  • 19.16. LGC Biosearch Technologies
  • 19.17. Merck KGaA
  • 19.18. Meridian Bioscience, Inc
  • 19.19. New England Biolabs, Inc
  • 19.20. NimaGen B.V.
  • 19.21. Omega Bio-tek, Inc.
  • 19.22. Oxford Nanopore Technologies PLC
  • 19.23. Pacific Biosciences of California, Inc.
  • 19.24. Parse Biosciences
  • 19.25. PerkinElmer, Inc.
  • 19.26. Promega Corporation
  • 19.27. QIAGEN N.V.
  • 19.28. Standard BioTools Inc.
  • 19.29. Takara Bio Inc.
  • 19.30. Thermo Fisher Scientific, Inc.
  • 19.31. Twist Bioscience Corporation
  • 19.32. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY PREPARATION & AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY LIBRARY QUANTIFICATION/QC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NUCLEIC ACID EXTRACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGET ENRICHMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CHIP SEQUENCING (CHROMATIN IMMUNOPRECIPITATION), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY METHYLATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA SEQUENCING (RNA-SEQ), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY AGRICULTURAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ANIMAL SCIENCE & VETERINARY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CLINICAL RESEARCH & DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY CONSUMER GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY FORENSICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 148. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. GCC NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 169. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. G7 NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 176. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY NGS TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA NEXT-GENERATION SEQUENCING SAMPLE PREPARATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)